Prot #AG221-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date4/8/14 → 4/30/21

Funding

  • INC Research, LLC (Prot #AG221-C-001)
  • Agios Pharmaceuticals, Inc. (Prot #AG221-C-001)